使用抗血管内皮生长因子（anti-VEGF）和玻璃体内注射类固醇治疗戊聚糖多硫酸盐黄斑病变继发的黄斑囊样水肿。
Treatment of cystoid macular oedema secondary to pentosan polysulfate maculopathy using anti-VEGF and intravitreal steroid injections.
作者信息
De Silva Samantha Roshani, De Silva Isuru, Pal Bishwanath
机构信息
Medical Retina Service, 4960Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Institute of Ophthalmology, University College London, London, UK.
出版信息
Eur J Ophthalmol. 2021 Dec 6:11206721211066387. doi: 10.1177/11206721211066387.
BACKGROUND
Pentosan polysulfate-related maculopathy is a recently described clinical entity, related to dose and long term use of this medication, and may progress despite drug cessation. Cystoid macular oedema (CMO) has been reported in some cases, but there are few reports of treatment outcomes in the literature.
AIMS
We present the case of a 55 year old female, with CMO secondary to pentosan polysulfate maculopathy, that was responsive to treatment with both intravitreal anti-VEGF and steroid injections, stabilising vision over a four year follow up period.
CONCLUSIONS
This is the first report, to our knowledge, of CMO related to pentosan polysulfate maculopathy responding to intravitreal steroid injections, broadening the therapeutic options for preserving vision in these patients.
背景
戊聚糖多硫酸盐相关性黄斑病变是一种最近描述的临床病症，与该药物的剂量和长期使用有关，并且即使停药也可能进展。在一些病例中已报道有黄斑囊样水肿（CMO），但文献中关于治疗结果的报道很少。
目的
我们报告一例55岁女性患者，患有继发于戊聚糖多硫酸盐黄斑病变的CMO，其对玻璃体内抗血管内皮生长因子（VEGF）和类固醇注射治疗均有反应，在四年的随访期内视力稳定。
结论
据我们所知，这是第一份关于与戊聚糖多硫酸盐黄斑病变相关的CMO对玻璃体内类固醇注射有反应的报告，拓宽了这些患者保留视力的治疗选择。
Zotero 插件